Hartmann Research is the first firm dedicated exclusively to equity research on animal health companies in the U.S. market. We blend insider veterinary expertise with rigorous financial analysis to fill a growing gap: ongoing, independent, and specialized coverage of the animal health industry, free from conflicts of interest and stock recommendations.
Hartmann was founded by Gabriel Andrade, a veterinarian trained at the University of São Paulo (FZEA/USP), with an international exchange program in corporate strategy (Católica Lisbon), and training in valuation (FEA-USP).
Delivering independent research on publicly traded animal health companies in the United States for a broad segment of clients.
To become the most trusted source of fundamental insights for investors in the animal health sector.
Excellence for navigating complex markets. Integrity for eliminating biased advice. Precision for confident decisions.
Our reports combine veterinary expertise with in-depth company analysis, providing a deep understanding of each business’s fundamentals to empower strategic decisions in the animal health market.
ZTSELANPAHCIDXXTRUPCHWYFRPTNEOGHartmann Research is establishing itself as a trusted, independent provider of equity research focused on the animal health industry. Our proposal includes:
As a Founding Member, you'll also receive special discounts and early access to our reports.
Request Founding Member Access
Access to our research is reserved for clients. Click here to login, or contact us to request a sample or learn more.
| Date | Company | Title |
|---|
Email: contact@hartmannresearch.com
Address:
Av. Brigadeiro Faria Lima, 4440 – Itaim Bibi
São Paulo – SP, 04538-132, Brazil
Hartmann Research operates remotely, with presence in São Paulo’s financial district.
Please contact our team at contact@hartmannresearch.com to request a sample report or discuss subscription options.
Yes. We use an adjusted Gordon model and provide return expectations under different scenarios. When appropriate, we may also apply discounted cash flow (DCF) analysis to estimate the fair value of the stock. However, no report should be interpreted as a buy or sell recommendation. All projections are subject to uncertainty, and there are inherent risks in any valuation process.
Clients have access to direct analyst support for clarifications and in-depth discussions to maximize the value of our research.
Founding Members are early partners who receive special pricing and early access to research as part of their contribution to shaping our platform.